Protective effects of intermedin on cardiovascular, pulmonary and renal diseases: Comparison with adrenomedullin and CGRP

Current Protein and Peptide Science

Volumn 14, Issue 4, 2013, Pages 294-329

  Holmes, David ^a   Campbell, Malcolm ^a   Harbinson, Mark ^a   Bell, David ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Adrenomedullin; CGRP; Heart; Hypertrophy; Intermedin adrenomedullin 2; Ischaemia reperfusion; Kidney; Oxidative stress

Indexed keywords

ADRENOMEDULLIN; ADRENOMEDULLIN 1; ADRENOMEDULLIN 2; CALCITONIN GENE RELATED PEPTIDE; CYCLIC GMP DEPENDENT PROTEIN KINASE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERMEDIN; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; DIURESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SILENCING; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; MIGRAINE; NATRIURESIS; NERVE CONDUCTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; RADIOIMMUNOASSAY; REPERFUSION INJURY; SEQUENCE HOMOLOGY; SYSTEMIC BLOOD PRESSURE; VASCULARIZATION; VASODILATATION;

ADRENOMEDULLIN; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; INFLAMMATION; KIDNEY DISEASES; LUNG DISEASES; ORGAN SPECIFICITY; OXIDATIVE STRESS; PEPTIDE HORMONES; PROTECTIVE AGENTS; RECEPTORS, ADRENOMEDULLIN; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; REPERFUSION INJURY;

EID: 84888223228     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/13892037113149990049     Document Type: Article

References (328)

1. Rosenfeld M.G.; Mermod J.J.; Amara S.G.; Swanson L.W.; Sawchenko P.E.; Rivier J.; Vale W.W.; Evans R.M., Production of a novel neuropeptide encoded by the calcitonin gene via tissuespecific RNA processing. Nature, 1983, 304, 129-135.
2. Alevizaki, M.; Shiraishi, A.; Rassool, F.V.; Ferrier, G. J; MacIntyre, I.; Legon, S. The calcitonin-like sequence of the beta CGRP gene. FEBS Lett., 1986, 206(1), 47-52.
3. Brain, S.D.; Grant, A.D. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev., 2004, 84(3), 903-934.
4. Roh, J.; Chang, C.L.; Bhalla, A.; Klein, C.; Hsu, S.Y. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activitymodifying protein receptor complexes. J. Biol. Chem., 2004, 279(8), 7264-7274.
5. Takei, Y.; Inoue, K.; Ogoshi, M.; Kawahara, T.; Bannai, H.; Miyano, S. Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Lett., 2004, 556(1-3), 53-58.
6. Kitamura, K.; Kangawa, K.; Ishiyama, Y.; Washimine, H.; Ichiki, Y.; Kawamoto, M.; Minamino, N.; Matsuo, H.; Eto, T. Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP). FEBS Lett., 1994, 351(1), 35-37.
7. Bell, D.; McDermott, B.J. Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems. Br. J. Pharmacol., 2008, 153(S1), 247-262.
8. Takahashi, K.; Morimoto, R.; Hirose, T.; Satoh, F.; Totsune, K. Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis. J. Mol. Neurosci., 2011, 43(2), 182-192.
9. Chauhan, M.; Yallampalli, U.; Dong, Y.; Hankins, G.D.; Yallampalli, C. Expression of Adrenomedullin 2 (ADM2)/intermedin (IMD) in human placenta: role in trophoblast invasion and migration. Biol. Reprod., 2009, 81(4), 777-783.
10. Chauhan, M.; Elkins, R.; Balakrishnan, M.; Yallampalli, C. Potential role of intermedin/adrenomedullin 2 in early embryonic development in rats. Regul. Pept., 2011, 170(1-3), 65-71.
11. Chang, C.L.; Wang, H.; Soong, Y.; Huang, S.Y.; Pai, S.Y.; Hsu, S.Y. Regulation of oocyte and cumulus cell interactions by intermedin/ adrenomedullin 2. J. Biol. Chem., 2011, 286(50), 43193-43203.
12. Granholm, S.; Henning, P.; Lerner, U. H. Comparisons between the effects of calcitonin receptor-stimulating peptide and intermedin and other peptides in the calcitonin family on bone resorption and osteoclastogenesis. J. Cell. Biochem., 2011, 112(11), 3300-3312.
13. Hong, Y.; Hay, D.L.; Quirion, R.; Poyner, D.R. The pharmacology of adrenomedullin 2/intermedin. Br. J. Pharmacol., 2012, 166(1), 110-120.
14. Bell, D.; McDermott, B.J. Calcitonin gene-related peptide in the cardiovascular system: characterization of receptor populations and their (patho)physiological significance. Pharmacol. Rev., 1996, 48(2), 253-288.
15. Smillie, S.; Brain, S.D. Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides, 2011, 45(2), 93-104.
16. Deville, J.L.; Salas, S.; Figarella-Branger, D.; Ouafik, L.; Daniel, L. Adrenomedullin as a therapeutic target in angiogenesis. Expert Opin. Ther. Targets, 2010, 14(10), 1059-1072.
17. Salvatore, C.A.; Kane, S.A. CGRP receptor antagonists: toward a novel migraine therapy. Curr. Pharm. Biotechnol., 2011, 12(10), 1671-1680.
18. Petermann, J.B.; Born, W.; Chang, J.Y.; Fischer, J.A. Identification in the human central nervous system, pituitary, and thyroid of a novel calcitonin gene-related peptide, and partial amino acid sequence in the spinal cord. J. Biol. Chem., 1987, 262(2), 542-545.
19. Mulderry, P.K.; Ghatei, M.A.; Spokes, R.A.; Jones, P.M.; Pierson, A.M.; Hamid, Q.A.; Kanse, S.; Amara, S.G.; Burrin, J.M.; Legon, S. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience, 1988, 25(1), 195-205.
20. Asada, Y.; Hara, S.; Marutsuka, K.; Kitamura, K.; Tsuji, T.; Sakata, J.; Sato, Y.; Kisanuki, A.; Eto, T.; Sumiyoshi, A. Novel distribution of adrenomedullin-immunoreactive cells in human tissues. Histochem. Cell Biol., 1999, 112(3), 185-191.
21. Zhou, M.; Chaudry, I.H.; Wang, P. The small intestine is an important source of adrenomedullin release during polymicrobial sepsis. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 281(2), R654-R660.
22. Hinson, J.P.; Kapas, S.; Smith, D.M. Adrenomedullin, a multifunctional regulatory peptide. Endocr. Rev., 2000, 21(2), 138-167.
23. Li W, Hou L, Hua Z, Wang X. Interleukin-1beta induces beta-CGRP secretion in human type II alveolar epithelial cells. FASEB J, 2004, 18, 1603-1605.
24. Jakab G, Webster HD, Salamon I, Mezey E. Neural and non-neural origin of CGRP in the gastric mucosa. Neuropeptides, 1993, 24, 117-122.
25. Franco-Cereceda, A.; Henke, H.; Lundberg, J.M.; Petermann, J.B.; Hökfelt, T.; Fischer, J.A. Calcitonin gene-related peptide (CGRP) in capsaicin-sensitive substance P-immunoreactive sensory neurons in animals and man: distribution and release by capsaicin. Peptides, 1987, 8(2), 399-410.
26. Ichiki, Y.; Kitamura, K.; Kangawa, K.; Kawamoto, M.; Matsuo, H.; Eto, T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett., 1994, 338(1), 6-10.
27. Takahashi, K.; Kikuchi, K.; Maruyama, Y.; Urabe, T.; Nakajima, K.; Sasano, H.; Imai, Y.; Murakami, O.; Totsune, K. Immunocytochemical localization of adrenomedullin 2/intermedin-like immunoreactivity in human hypothalamus, heart and kidney. Peptides, 2006, 27(6), 1383-1389.
28. Onuoha, G.N.; Nicholls, D.P.; Alpar, E.K.; Ritchie, A.; Shaw, C.; Buchanan, K. Regulatory peptides in the heart and major vessels of man and mammals. Neuropeptides, 1999, 33(2), 165-172.
29. Morimoto, R.; Satoh, F.; Murakami, O.; Totsune, K.; Suzuki, T.; Sasano, H.; Ito, S.; Takahashi, K. Expression of adrenomedullin2/ intermedin in human brain, heart, and kidney. Peptides, 2007, 28(5), 1095-1103.
30. Jougasaki, M.; Wei, C.; McKinley, L.J.; Burnett, J.C. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation, 1995, 92(3), 286-289.
31. 1-receptor-dependent protection by intermedin of human vascular and cardiac nonvascular cells from ischaemia-reperfusion injury. J. Physiol., 2012, 590(5), 1181-1197.
32. Gulbenkian, S.; Saetrum Opgaard, O.; Ekman, R.; Costa-Andrade, N.; Wharton, J.; Polak, J.M.; Queiroze Melo, J.; Edvinsson, L. Peptidergic innervation of human epicardial coronary arteries. Circ. Res., 1993, 73(3), 579-588.
33. Pearson, L.J.; Yandle, T.G.; Nicholls, M.G.; Evans, J.J. Intermedin (adrenomedullin-2): a potential protective role in human aortic endothelial cells. Cell Physiol. Biochem., 2009, 23(1-3), 97-108.
34. Gupta, R.; Ahmed, T.; Banerjee, B.; Bhatia, M. Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period. J. Headache Pain, 2009, 10(3), 161-166.
35. Kitamura, K.; Kangawa, K.; Kawamoto, M.; Ichiki, Y.; Nakamura, S.; Matsuo, H.; Eto, T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun., 1993, 192(2), 553-560.
36. Geppetti, P.; Baldi, E.; Manzini, S.; Del Bianco, E.; Maggi, C.A.; Natali, A.; Mannelli, M. Regional differences of adenylate cyclase stimulation by calcitonin and calcitonin gene-related peptide in the human kidney. J. Clin. Endocrinol. Metab., 1989, 69(3), 491-495.
37. Hua, X.Y.; Theodorsson-Norheim, E.; Lundberg, J.M.; Kinn, A.C.; Hökfelt, T.; Cuello, A.C. Co-localization of tachykinins and calcitonin gene-related peptide in capsaicin-sensitive afferents in relation to motility effects on the human ureter in vitro. Neuroscience, 1987, 23(2), 693-703.
38. Lai, K.N.; Leung, J.C.; Yeung, V.T.; Lewis, L.K.; Nicholls, M.G. Gene transcription and synthesis of adrenomedullin by cultured human renal cells. Biochem. Biophys. Res. Commun., 1998, 244(2), 567-572.
39. Marutsuka, K.; Hatakeyama, K.; Sato, Y.; Yamashita, A.; Sumiyoshi, A.; Asada, Y. Immunohistological localization and possible functions of adrenomedullin. Hypertens. Res., 2003, 26(Suppl.), S33-S40.
40. Martling, C.R.; Saria, A.; Fischer, J.A.; Hökfelt, T.; Lundberg, J.M. Calcitonin gene-related peptide and the lung: neuronal coexistence with substance P, release by capsaicin and vasodilatory effect. Regul. Pept., 1988, 20(2), 125-139.
41. Martinez, A.; Miller, M.J.; Unsworth, E.J.; Siegfried, J.M.; Cuttitta, F. Expression of adrenomedullin in normal human lung and in pulmonary tumors. Endocrinology, 1995, 136(9), 4099-4105.
42. Edvinsson, L.; Ekman, R.; Jansen, I.; Ottosson, A.; Uddman, R. Peptide-containing nerve fibers in human cerebral arteries: immunocytochemistry, radioimmunoassay, and in vitro pharmacology. Ann. Neurol., 1987, 21(5), 431-437.
43. Boscolo, E.; Pavesi, G.; Zampieri, P.; Conconi, M.T.; Calore, C.; Scienza, R.; Parnigotto, P.P.; Folin, M. Endothelial cells from human cerebral aneurysm and arteriovenous malformation release ET-1 in response to vessel rupture. Int. J. Mol. Med., 2006, 18(5), 813-819.
44. Morimoto, R.; Satoh, F.; Murakami, O.; Hirose, T.; Totsune, K.; Imai, Y.; Arai, Y.; Suzuki, T.; Sasano, H.; Ito, S.; Takahashi, K. Expression of adrenomedullin 2/intermedin in human adrenal tumors and attached non-neoplastic adrenal tissues. J Endocrinol., 2008, 198(1), 175-183.
45. Kindt, F.; Wiegand, S.; Loser, C.; Nilles, M.; Niemeier, V.; Hsu, S.Y.; Stenihoff, M.; Kummer, W.; Gieler, U.; Haberberger, R.V. Intermedin: a skin peptide that is downregulated in atopic dermatitis. J. Invest. Dermatol., 2006, 127(3), 605-613.
46. Connat J.L.; Busseuil, D.; Gambert, S.; Ody, M.; Tébaldini, M.; Gamboni, S.; Faivre, B.; Quiquerez, A.L.; Millet, M.; Michaut, P.; Rochette, L. Modification of the rat aortic wall during ageing; possible relation with decrease of peptidergic innervation. Anat. Embryol. (Berl.), 2001, 204(6), 455-468.
47. Doi, Y.; Kudo, H.; Nishino, T.; Kayashima, K.; Kiyonaga, H.; Nagata, T.; Nara, S.; Morita, M.; Fujimoto, S. Synthesis of calcitonin gene-related peptide (CGRP) by rat arterial endothelial cells. Histol. Histopathol., 2001, 16(4), 1073-1079.
48. Zhou Z, Hu C-P, Wang C-J, Li T-T, Peng J, Li Y-J. Calcitionin gene-related peptide inhibits angiotensin II-induced endothelial progenitor cells senescence through up-regulation of klotho expression. Atherosclerosis, 2010, 213, 92-101.
49. Luo D, Zhang Y-W, Peng W-J, Peng J, Chen Q-Q, Li D, Deng HW, Li Y-J. Transient receptor potential vanilloid 1-mediated expression and secretion of endothelial cell-derived calcitonin generelated peptide. Reg Pept, 2008, 150, 66-72.
50. Goadsby, P.J.; Edvinsson, L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol., 1993, 33(1), 48-56.
51. Lang MG, Paterno R, Faraci FM, Heistad DD. Mechanisms of adrenomedullin-induced dilatation of cerebral arterioles. Stroke, 1997, 28 (1) 181-185.
52. Baskaya, M.K.; Suzuki, Y.; Anzai, M.; Seki, Y.; Saito, K.; Takayasu, M.; Shibuya, M.; Sugita, K. Effects of adrenomedullin, calcitonin gene-related peptide, and amylin on cerebral circulation in dogs. J. Cereb. Blood Flow. Metab., 1995, 15(5), 827-834.
53. Mori, Y.; Takayasu, M.; Suzuki, Y.; Shibuya, M.; Yoshida, J.; Hidaka, H. Effects of adrenomedullin on rat cerebral arterioles. Eur. J. Pharmacol., 1997, 330(2-3), 195-198.
54. Takao, M.; Tomita, M.; Tanahashi, N.; Kobari, M.; Fukuuchi, Y. Transient vasodilatory effects of adrenomedullin on cerebral parenchymal microvessels in cats. Neurosci. Lett., 1999, 268(3), 147-150.
55. Kis, B.; Kaiya, H.; Nishi, R.; Deli, M.A.; Abrahám, C.S.; Yanagita, T.; Isse, T.; Gotoh, S.; Kobayashi, H.; Wada, A.; Niwa, M.; Kangawa, K.; Greenwood, J.; Yamashita, H.; Ueta, Y. Cerebral endothelial cells are a major source of adrenomedullin. J. Neuroendocrinol., 2002, 14(4), 283-293.
56. Kastin, A.J.; Akerstrom, V.; Hackler, L.; Pan, W. Adrenomedullin and the blood-brain barrier. Horm. Metab. Res., 2001, 33(1), 19-25.
57. Serrano, J.; Fernández, A.P.; Sánchez, J.; Rodrigo, J.; Martínez, A. Adrenomedullin expression is up-regulated by acute hypobaric hypoxia in the cerebral cortex of the adult rat. Brain Pathol., 2008, 18(3), 434-442.
58. Takahashi, K.; Nakayama, M.; Totsune, K.; Murakami, O.; Sone, M.; Kitamuro, T.; Yoshinoya, A.; Shibahara, S. Increased secretion of adrenomedullin from cultured human astrocytes by cytokines. J. Neurochem., 2000, 74(1), 99-103.
59. Hashimoto, H.; Kitamura, K.; Kawasaki, M.; Saito, T.; Suzuki, H.; Otsubo, H.; Ohbuchi, T.; Yokoyama, T.; Fujihara, H.; Takei, Y.; Ueta, Y. Adrenomedullin 2/intermedin-like immunoreactivity in the hypothalamus and brainstem of rats. Auton. Neurosci., 2008, 139(1-2), 46-54.
60. Chen, L.; Kis, B.; Hashimoto, H.; Busija, D.W.; Takei, Y.; Yamashita, H.; Ueta, Y. Adrenomedullin 2 protects rat cerebral endothelial cells from oxidative damage in vitro. Brain Res., 2006; 1086(1), 42-49.
61. Taylor M.M.; Bagley S.L.; Samson W.K. Intermedin/ adrenomedullin-2 acts within central nervous system to elevate blood pressure and inhibit food and water intake. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 288(4), R919-R927.
62. Pfeil, U.; Aslam, M.; Paddenberg, R.; Quanz, K.; Chang C.L.; Park, J.I.; Gries, B.; Rafiq, A.; Faulhammer, P.; Goldenberg, A.; Papadakis, T.; Noll, T.; Hsu, S.Y.; Weissmann, N.; Kummer, W. Intermedin/adrenomedullin-2 is a hypoxia-induced endothelial peptide that stabilizes pulmonary microvascular permeability. Am. J. Physiol. Lung Cell. Mol. Physiol., 2009, 297(5), L837-L845.
63. Upton P.D.; Wharton, J.; Coppock, H.; Davie, N.; Yang, X.; Yacoub, M.H.; Ghatei, M.A.; Polak, J.M.; Bloom, S.R.; Smith, D.M.; Morrell, N.W. Adrenomedullin expression and growth inhibitory effects in distinct pulmonary artery smooth muscle cell subpopulations. Am. J. Respir. Cell Mol. Biol., 2001, 24(2), 170-178.
64. Sakata, J.; Shimokubo, T.; Kitamura, K.; Nishizono, M.; Iehiki, Y.; Kangawa, K.; Matsuo, H.; Eto, T. Distribution and characterization of immunoreactive rat adrenomedullin in tissue and plasma. FEBS Lett., 1994, 352(2), 105-108.
65. Verastegui, C.; Prada Oliveira, A.; Fernandez-Vivero, J.; Romero, A.; de Castro, J.M. Calcitonin gene-related peptide immunoreactivity in adult mouse lung. Eur. J. Histochem., 1997, 41(2), 119-126.
66. Komatsu, T.; Yamamoto, M.; Shimokata, K.; Nagura, H. Distribution of substance P-immunoreactive and calcitonin gene-related peptide-immunoreactive nerves in normal human lungs. Int. Arch. Allergy Appl. Immunol., 1991, 95(1), 23-28.
67. Tsutsumi, Y. Immunohistochemical analysis of calcitonin and calcitonin gene-related peptide in human lung. Hum. Pathol., 1989, 20(9), 896-902.
68. Johnson, D.E.; Wobken, J.D. Calcitonin gene-related peptide immunoreactivity in airway epithelial cells of the human fetus and infant. Cell Tissue Res., 1987, 250(3), 579-583.
69. Takei, Y.; Hyodo, S.; Katafuchi, T.; Minamino, N. Novel fishderived adrenomedullin in mammals: structure and possible function. Peptides, 2004, 25(10), 1643-1656.
70. Pan, C.S.; Yang, J.H.; Cai, D.Y.; Zhao, J.; Gerns, H.; Yang, J.; Chang, J.K.;Tang, C.S.; Qi, Y.F. Cardiovascular effects of newly discovered peptide intermedin/adrenomedullin 2. Peptides, 2005, 26(9), 1640-1646.
71. Zhao, Y.; Bell, D.; Smith, L.R.; Zhao, L.; Devine, A.B.; McHenry, E.M.; Nicholls, D.P.; McDermott, B.J. Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxidedeficient hypertension. J. Pharmacol. Exp. Ther., 2006, 316(3), 1269-1281.
72. Nakayama, M.; Takahashi, K.; Murakami, O.; Shirato, K.; Shibahara, S. Induction of adrenomedullin by hypoxia in cultured human coronary artery endothelial cells. Peptides, 1999, 20(6), 769-772.
73. Bell, D.; McDermott, B.J. Secretin and vasoactive intestinal peptide are potent stimulants of cellular contraction and accumulation of cyclic AMP in rat ventricular cardiomyocytes. J. Cardiovasc. Pharmacol., 1994, 23(6), 959-969.
74. Saetrum Opgaard O.; Gulbenkian, S.; Bergdahl, A.; Barroso, C.; Andrade, N.C.; Polak, J. M; Queiroze Melo, J.Q.; Edvinsson, L. Innervation of human epicardial coronary veins: immunohistochemistry and vasomotility. Cardiovasc. Res., 1995, 29(4), 463-468.
75. Diez Guerra, F.J.; Zaidi, M.; Bevis, P.; MacIntyre, I.; Emson, P.C. Evidence for release of calcitonin gene-related peptide and neurokinin A from sensory nerve endings in vivo. Neuroscience, 1988, 25(3), 839-846.
76. Sugo, S.; Minamino, N.; Shoji, H.; Kangawa, K.; Kitamura, K.; Eto, T.; Matsuo, H. Production and secretion of adrenomedullin from vascular smooth-muscle cells: augmented production by tumor necrosis factor-α. Biochem. Biophys. Res. Commun., 1994, 203(1), 719-726.
77. Sugo, S.; Minamino, N.; Kangawa, K.; Miyamoto, K.; Kitamura, K.; Sakata, J.; Eto, T.; Matsuo, H. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem. Biophys. Res. Commun., 1994, 201(3), 1160-1166.
78. Hobara, N.; Nakamura, A.; Ohtsuka, A.; Narasaki, M.; Shibata, K.; Gomoita, Y.; Kawasaki, H. Distribution of adrenomedullincontaining perivascular nerves in the rat mesenteric artery. Peptides, 2004, 25(4), 589-599.
79. Gupta, P.; Harte, A.L.; da Silva, N.F.; Khan, H.; Barnett, A.H.; Kumar, S.; Sturdee, D.W.; McTernan, P.G. Expression of calcitonin gene-related peptide, adrenomedullin, and receptor modifying proteins in human adipose tissue and alteration in their expression with menopause status. Menopause, 2007, 14(6), 1031-1038.
80. Hirose, T.; Totsune, K.; Mori, N.; Mori, T.; Morimoto, R.; Metoki, H.; Asayama, K.; Kikuya, M.; Ohkubo, T.; Kohzuki, M.; Takahashi, K.; Imai, Y. Expression of adrenomedullin 2/intermedin, a possible reno-protective peptide, is decreased in the kidneys of rats with hypertension or renal failure. Am. J. Physiol. Renal Physiol., 2010, 299(1), F128-F134.
81. Liu, X.; Zhang, Z.; Zhang, X.; Zhu, H.; Chen, Q.; Guo, M. The localization of adrenomedullin in rat kidney tissue and its inhibitory effect on the growth of cultured rat mesangial cells. Chin. Med. Sci. J., 2002, 17(3), 129-133.
82. Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr. Med. Chem., 2007, 14(15), 1689-1699.
83. Chini, E.N.; Chini, C.C.; Bolliger, C.; Jougasaki, M.; Grande, J.P.; Burnett, J.C. Jr.; Dousa, T.P. Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway. Kidney Int., 1997, 52(4), 917-925.
84. Jougasaki, M.; Burnett, J.C. Jr. Adrenomedullin: Potential in physiology and pathophysiology. Life Sci., 2000, 66(10), 855-872.
85. Knight D.S.; Cicero, S.; Beal, J.A. Calcitonin gene-related peptideimmunoreactive nerves in the rat kidney. Am. J. Anat., 1991, 190(1), 31-40.
86. Harmancey, R.; Senard, J.M.; Pathak, A.; Desmoulin, F.; Claparols, C.; Rouet, P.; Smih, F. The vasoactive peptide adrenomedullin is secreted by adipocytes and inhibits lipolysis through NO-mediated β-adrenergic agonist oxidation. FASEB J., 2005, 19(8), 1045-1047.
87. Letizia, C.; Iacobellis, G.; Caliumi, C.; Leonetti, F.; Cotesta, D.; Ribaudo, M.C.; Petramala, L.; Cianci, R.; Celi, M.; D'Erasmo, E.; Di Mario, U. Acute hyperinsulinemia is associated with increased plasma adrenomedullin concentrations in uncomplicated obesity. Exp. Clin. Endocrinol. Diabetes, 2005, 113(3), 171-175.
88. Zaidi, M.; Bevis, P.J.; Girgis, S.I.; Lynch, C.; Stevenson, J.C.; Macintyre, I. Circulating CGRP comes from the perivascular nerves. Eur. J. Pharmacol., 1985, 117(2), 283-284.
89. Girgis, S.I.; Macdonald, D.W.; Stevenson, J.C.; Bevis, P.J.; Lynch, C.; Wimalawansa, S.J.; Self, C.H.; Morris, H.R.; MacIntyre, I. Calcitonin gene-related peptide: potent vasodilator and major product of calcitonin gene. Lancet, 1985, 2(8445), 14-16.
90. Chang, C.L.; Roh, J.; Hsu, S.Y. Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: A comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides, 2004, 25(10), 1633-1642.
91. McLatchie, L.M.; Fraser, N.J.; Main, M.J.; Wise, A.; Brown, J.; Thompson, N.; Solari, R.; Lee, M.G.; Foord, S.M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature, 1998, 393(6683), 333-339.
92. Kuwasako, K.; Cao, Y.; Nagoshi, Y.; Tsuruda, T.; Kitamura, K.; Eto, T. Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins. Mol. Pharmacol., 2004, 65(1), 207-213.
93. Nishimatsu, H.; Suzuki, E.; Nagata, D.; Moriyama, N.; Satonaka, H.; Walsh, K.; Sata, M.; Kangawa, K.; Matsuo, H.; Goto, A.; Kitamura, T.; Hirata, Y. Adrenomedullin induces endotheliumdependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta. Circ. Res., 2001, 89(1), 63-70.
94. Bell, D.; Schlüter, K.; Zhou, X.; McDermott, B.J.; Piper, M.H. Hypertrophic effects of calcitonin gene-related peptide (CGRP) and amylin on adult mammalian ventricular cardiomyocytes. J. Mol. Cell. Cardiol., 1995, 27(11), 2433-2443.
95. Poyner, D.R.; Sexton, P.M.; Marshall, I.; Smith, D.M.; Quirion, R.; Born, W.; Muff, R.; Fischer, J.A.; Foord, S.M. International union of pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev., 2002, 54(2), 233-246.
96. Hay, D.L.; Christopoulos, G.; Christopoulos, A.; Poyner, D.R.; Sexton, P.M. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol., 2005, 67(5), 1655-1665.
97. Owji, A.; Chabot, J.; Dumont, Y.; Quirion, R. Adrenomedullin-2/intermedin induces cAMP accumulation in dissociated rat spinal cord cells: evidence for the existence of a distinct class of sites of action. J. Mol. Neurosci., 2008, 35(3), 355-361.
98. Taylor, M.M.; Bagley, S.L.; Samson, W.K. Intermedin/ adrenomedullin-2 inhibits growth hormone release from cultured, primary anterior pituitary cells. Endocrinology, 2006, 147(2), 859-864.
99. Zeng, Q.; Yuan, Y.; Wang, X.; Wu, H.M.; Fan, L.; Qi, Y.F.; Tang, C.S.; Cai, Y.; Pan, C.S. Upregulated expression of intermedin and its receptor in the myocardium and aorta in spontaneously hypertensive rats. Peptides, 2009, 30(2), 391-399.
100. Hay, D.L.; Howitt, S.G.; Conner, A.C.; Schindler, M.; Smith, D.M.; Poyner, D.R. CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS. Br. J. Pharmacol., 2003, 140(3), 477-486.
101. ter Haar, E.; Koth, C.M.; Abdul-Manan, N.; Swenson, L.; Coll, J.T.; Lippke, J.A.; Lepre, C.A.; Garcia-Guzman, M.; Moore, J.M. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure, 2010, 18(9), 1083-1093.
102. Hagner, S.; Stahl, U.; Knoblauch, B.; McGregor, G.P.; Lang, R.E. Calcitonin receptor-like receptor: identification and distribution in human peripheral tissues. Cell Tissue Res., 2002, 310(1), 41-50.
103. Nikitenko, L.L.; Blucher, N.; Fox, S.B.; Bicknell, R.; Smith, D.M.; Rees, M.C. Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms. J. Cell Sci., 2006, 119(5), 910-922.
104. Hagner, S.; Haberberger, R.; Kummer, W.; Springer, J.; Fischer, A.; Böhm, S.; Göke, B.; McGregor, G.P. Immunohistochemical detection of calcitonin gene-related peptide receptor (CGRPR)-1 in the endothelium of human coronary artery and bronchial blood vessels. Neuropeptides, 2001, 35(1), 58-64.
105. Nagae, T.; Mukoyama, M.; Sugawara, A.; Mori, K.; Yahata, K.; Kasahara, M.; Suganami, T.; Makino, H.; Fujinaga, Y.; Yoshioka, T.; Tanaka, I.; Nakao, K. Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin/CGRP receptor: cloning and upregulation in obstructive nephropathy. Biochem. Biophys. Res. Commun., 2000, 270(1), 89-93.
106. Cottrell, G.S.; Roosterman, D.; Marvizon, J.; Song, B.; Wick, E.; Pikios, S.; Wong, H.; Berthelier, C.; Tang, Y.; Sternini, C.; Bunnett, N.W.; Grady, E.F. Localization of calcitonin receptor-like receptor and receptor activity modifying protein 1 in enteric neurons, dorsal root ganglia, and the spinal cord of the rat. J. Comp. Neurol., 2005, 490(3), 239-255.
107. Chakravarty, P.; Suthar, T.P.; Coppock, H.A.; Nicholl, C.G.; Bloom, S.R.; Legon, S.; Smith, D.M. CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues. Br. J. Pharmacol., 2000, 130(1), 189-195.
108. Oliver, K.R.; Wainwright, A.; Edvinsson, L.; Pickard, J.D.; Hill, R.G. Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J. Cereb. Blood Flow Metab., 2002, 22(5), 620-629.
109. Kamitani, S.; Asakawa, M.; Shimekake, Y.; Kuwasako, K.; Nakahara, K.; Sakata, T. The RAMP2/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells. FEBS Lett., 1999, 448(1), 111-114.
110. Autelitano, D.J.; Ridings, R. Adrenomedullin signalling in cardiomyocytes is dependent upon CRLR and RAMP2 expression. Peptides, 2001, 22(11), 1851-1857.
111. Christopoulos, A.; Christopoulos, G; Morfis, M.; Udawela, M.; Laburthe, M.; Couvineau, A.; Kuwasako, K.; Tilakaratne, N.; Sexton, P.M. Novel receptor partners and function of receptor activity-modifying proteins. J. Biol. Chem., 2003, 278(5), 3293-3297.
112. Udawela, M.; Hay, D.L.; Sexton, P.M. The receptor activity modifying protein family of G protein coupled receptor accessory proteins. Semin. Cell. Dev. Biol., 2004, 15(3), 299-308.
113. Husmann, K.; Sexton, P.M.; Fischer, J.A.; Born, W. Mouse receptor-activity-modifying proteins 1,-2 and-3: amino acid sequence, expression and function. Mol. Cell Endocrinol., 2000, 162(1-2), 35-43.
114. Oliver, K.R.; Kane, S.A.; Salvatore, C.A.; Mallee, J.J.; Kinsey, A.M.; Koblan, K.S.; Keyvan-Fouladi, N.; Heavens, R.P.; Wainwright, A.; Jacobson, M.; Dickerson, I.M.; Hill, R.G. Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat. Eur. J. Neurosci., 2001, 14(4), 618-628.
115. Harikumar, K.G.; Simms, J.; Christopoulos, G.; Sexton, P.M.; Miller, L.J. Molecular basis of association of receptor activitymodifying protein 3 with the family B G protein-coupled secretin receptor. Biochemistry, 2009, 48(49), 11773-11785.
116. Tfelt-Hansen, J.; Hansen, J.L.; Smajilovic, S.; Terwilliger, E.F.; Haunso, S.; Sheikh, S.P. Calcium receptor is functionally expressed in rat neonatal ventricular cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol., 2006, 290(3), H1165-H1171.
117. Sexton, P.M.; Morfis, M.; Tilakaratne, N.; Hay, D.L.; Udawela, M.; Christopoulos, G.; Christopoulos, A. Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs. Ann. N. Y. Acad. Sci., 2006, 1070, 90-104.
118. Kadmiel, M.; Fritz-Six, K.L.; Caron, K.M. Understanding RAMPs through genetically engineered mouse models. Adv. Exp. Med. Biol., 2012, 744, 49-60.
119. Doods, H.; Hallermayer, G.; Wu, D.; Entzeroth, M.; Rudolf, K.; Engel, W.; Eberlein, W. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol., 2000, 129(3), 420-423.
120. Fukuhara, M.;Tsuchihashi, T.; Abe, I.; Fujishima, M. Cardiovascular and neurohormonal effects of intravenous adrenomedullin in conscious rabbits. Am. J. Physiol. Regul. Integr. Comp. Physiol., 1995, 269(5), R1289-R1293.
121. Lainchbury, J.G.; Cooper, G.J.; Coy, D.H.; Jiang, N.Y.; Lewis, L.K.; Yandle, T.G.; Richards, A.M.; Nicholls, M.G. Adrenomedullin: a hypotensive hormone in man. Clin. Sci. (Lond.), 1997, 92(5), 467-472.
122. Gennari, C.; Fischer, J.A. Cardiovascular action of calcitonin generelated peptide in humans. Calcif. Tissue Int., 1985, 37(6), 581-584.
123. Franco-Cereceda, A.; Gennari, C.; Nami, R.; Agnusdei, D.; Pernow, J.; Lundberg, J.M.; Fischer, J.A. Cardiovascular effects of calcitonin gene-related peptides I and II in man. Circ. Res., 1987, 60(3), 393-397.
124. Gnaedinger, M.P.; Uehlinger, D.E.; Weidmann, P.; Sha, S.G.; Muff, R.; Born, W.; Rascher, W.; Fischer, J.A. Distinct hemodynamic and renal effects of calcitonin gene-related peptide and calcitonin in men. Am. J. Physiol. Endocrinol. Metab., 1989, 257(6), E848-E854.
125. Lainchbury, J.G.; Troughton, R.W.; Lewis, L.K.; Yandle, T.G.; Richards, A.M.; Nicholls, M.G. Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. J. Clin. Endocrinol. Metab., 2000, 85(3), 1016-1020.
126. Charles, C.J.; Rademaker, M.T.; Richards, A.M. Hemodynamic, hormonal, and renal actions of adrenomedullin-2 in normal conscious sheep. Endocrinology, 2006, 147(4), 1871-1877.
127. Ren, YS.; Yang, J.; Zhang, J.; Pan, C.; Yang, J.; Zhao, J.; Pang, Y.Z.; Tang, C.S.; Qi, Y.F. Intermedin1-53 in central nervous system elevates arterial blood pressure in rats. Peptides, 2006, 27(1), 74-79.
128. Fujisawa, Y.; Nagai, Y.; Miyatake, A.; Miura, K.; Shokoji, T.; Nishiyama, A.; Kimura, S.; Abe, Y. Roles of adrenomedullin-2 in regulating the cardiovascular and sympathetic nervous systems in conscious rats. Am. J. Physiol., 2006, 290(3), H1120-H1127.
129. Chauhan, M.; Ross, G.R.; Yallampalli, U.; Yallampalli, C. Adrenomedullin-2, a novel calcitonin/calcitonin-gene-related peptide family peptide, relaxes rat mesenteric artery: influence of pregnancy. Endocrinology, 2007, 148(4), 1727-1735.
130. Jolly, L.; March, J.; Kemp, P.; Bennett, T.; Gardiner, S. Mechanisms involved in the regional haemodynamic effects of intermedin (adrenomedullin 2) compared with adrenomedullin in conscious rats. Br. J. Pharmacol., 2009, 157(8), 1502-1513.
131. Fujisawa, Y.; Nagai, Y.; Miyatake, A.; Miura, K.; Nishiyama, A.; Kimura, S. Effects of adrenomedullin 2 on regional hemodynamics in conscious rats. Eur. J. Pharmacol., 2007, 558(1-3), 128-132.
132. Yang, J.H.; Jia, Y.; Pan, C.; Zhao, J.; Ouyang, M.; Yang, J.; Chang, J.K.; Tang, C.S.; Qi, Y.F. Effects of intermedin1-53 on cardiac function and ischemia/reperfusion injury in isolated rat hearts. Biochem. Biophys. Res. Commun., 2005, 327(3), 713-719.
133. Kobayashi, Y.; Liu, Y.; Gonda, T.; Takei, Y. Coronary vasodilatory response to a novel peptide, adrenomedullin 2. Clin. Exp. Pharmacol. Physiol., 2004, 31(Suppl. 2), S49-S50.
134. Kandilci, H.B.; Gumusel, B.; Wasserman, A.; Witriol, N.; Lippton, H. Intermedin/adrenomedullin-2 dilates the rat pulmonary vascular bed: Dependence on CGRP receptors and nitric oxide release. Peptides, 2006, 27(6), 1390-1396.
135. Kandilci, H.B.; Gumusel, B.; Lippton, H. Intermedin/ adrenomedullin-2 (IMD/AM2) relaxes rat main pulmonary arterial rings via cGMP-dependent pathway: Role of nitric oxide and large conductance calcium-activated potassium channels (BKCa). Peptides, 2008, 29(8), 1321-1328.
136. Abdelrahman, A.; Pang, C. Effect of intermedin/adrenomedullin-2 on venous tone in conscious rats. Naunyn-Schmiedeberg's Arch. Pharmacol., 2006, 373(5), 376-380.
137. Feng, C.J.; Kang, B.; Kaye, A.D.; Kadowitz, P.J.; Nossaman, B.D. L-NAME modulates responses to adrenomedullin in the hindquarters vascular bed of the rat. Life Sci., 1994, 55(22), L433-L438.
138. Minamino, N.; Kangawa, K.; Matsuo, H. Adrenomedullin: a new peptidergic regulator of the vascular function. Clin. Hemorheol. Microcirc., 2000, 23(2-4), 95-102.
139. Yang, J.H.; Pan, C.; Jia, Y.; Zhang, J.; Zhao, J.; Pang, Y.; Yang, J.; Tang, C.S.; Qi, Y.F. Intermedin1-53 activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Biochem. Biophys. Res. Commun., 2006, 341(2), 567-572.
140. Eguchi, S.; Hirata, Y.; Iwasaki, H.; Sato, K.; Watanabe, T.X.; Inui, T.; Nakajima, K.; Sakakibara, S.; Marumo, F. Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells. Endocrinology, 1994, 135(6), 2454-2458.
141. Lu, J.T.; Son, Y.; Lee, J.; Jetton, T.L.; Shiota, M.; Moscoso, L.; Niswender, K.D.; Loewy, A.D.; Magnuson, M.A.; Sanes, J.R.; Emeson, R.B. Mice lacking β-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol. Cell. Neurosci., 1999, 14(2), 99-120.
142. Gangula, P.R.; Zhao, H.; Supowit, S.C.; Wimalawansa, S.J.; Dipette, D.J.; Westlund, K.N.; Gagel, R.F.; Yallampalli, C. Increased blood pressure in β-calcitonin gene-related peptide/ calcitonin gene knockout mice. Hypertension, 2000, 35(1), 470-475.
143. Oh-hashi, Y.; Shindo, T.; Kurihara, Y.; Imai, T.; Wang, Y.; Morita, H.; Imai, Y.; Kayaba, Y.; Nishimatsu, H.; Suematsu, Y.; Hirata, Y.; Yazaki, Y.; Nagai, R.; Kuwaki, T.; Kurihara, H. Elevated sympathetic nervous activity in mice deficient in αCGRP. Circ. Res., 2001, 89(11), 983-990.
144. Petersen, K.A.; Birk, S.; Lassen, L.H.; Kruuse, C.; Jonassen, O.; Lesko, L.; Olesen, J. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia, 2005, 25(2), 139-147.
145. Huang R, Karve A, Shah I, Bowers MC, DiPette DJ, Supowit SC, Abela GS. Deletion of the mouse-CGRP gene increases the vulnerability of the heart to ischaemia-reperfusion injury. Am J Physiol-Heart, 2008, 294 (3), H1291-1297.
146. Caron, K.M.; Smithies, O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc. Natl. Acad. Sci. U S A, 2001, 98(2), 615-619.
147. Hay, D.L.; Smith, D.M. Adrenomedullin receptors: molecular identity and function. Peptides, 2001, 22(11), 1753-1763.
148. Dackor RT, Fritz-Six K, Dunworth WP, Gibbons CL, Smithies O, Caron KM. Hydrops fetalis, cardiovascular defects and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol Cell Biol, 2006, 26(7), 2511-2518.
149. Kadmiel M, Fritz-Six K, Pacharne S, Richards GO, Li M, Skerry TM, Caron KM. Haploinsufficiency of receptor activity modifying protein-2 causes reduced fertility, hyperprolactinemia, skeletal abnormalities and endocrine dysfunction in mice. Mol Endocrinol, 2011, 25(7), 1244-1253.
150. Shindo, T.; Kurihara, H.; Maemura, K.; Kurihara, Y.; Kuwaki, T.; Izumida, T.; Minamino, N.; Ju, K.H.; Morita, H.; Oh-hashi, Y.; Kumada, M.; Kangawa, K.; Nagai, R.; Yazaki, Y. Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature. Circulation, 2000, 101(19), 2309-2316.
151. Lippton, H.; Chang, J.K.; Hao, Q.; Summer, W.; Hyman, A.L. Adrenomedullin dilates the pulmonary vascular bed in vivo. J. Appl. Physiol., 1994, 76(5), 2154-2156.
152. Heaton, J.; Lin, B.; Chang, J.K.; Steinberg, S.; Hyman, A.; Lippton, H. Pulmonary vasodilation to adrenomedullin: a novel peptide in humans. Am. J. Physiol. Heart Circ. Physiol., 1995, 268(6), H2211-H2215.
153. Adnot, S.; Cigarini, I.; Herigault, R.; Harf, A. Effects of substance P and calcitonin gene-related peptide on the pulmonary circulation. J. Appl. Physiol., 1991, 70(4), 1707-1712.
154. DeWitt, B.J.; Cheng, D.Y.; Caminiti, G.N.; Nossaman, B.D.; Coy, D.H.; Murphy, W.A.; Kadowitz, P.J. Comparison of responses to adrenomedullin and calcitonin gene-related peptide in the pulmonary vascular bed of the cat. Eur. J. Pharmacol., 1994, 257(3), 303-306.
155. Nossaman, B.D.; Feng, C.J.; Cheng, D.Y.; Dewitt, B.J.; Coy, D.H.; Murphy, W.A.; Kadowitz, P.J. Comparative effects of adrenomedullin, an adrenomedullin analog, and CGRP in the pulmonary vascular bed of the cat and rat. Life Sci., 1995, 56(3), PL63-66.
156. Pinto, A.; Sekizawa, K.; Yamaya, M.; Ohrui, T.; Jia, Y.X.; Sasaki, H. Effects of adrenomedullin and calcitonin gene-related peptide on airway and pulmonary vascular smooth muscle in guinea-pigs. Br. J. Pharmacol., 1996, 119(7), 1477-1483.
157. Shirai, M.; Shimouchi, A.; Ikeda, S.; Ninomiya, I.; Sunagawa, K.; Kangawa, K.; Matsuo, H. Vasodilator effects of adrenomedullin on small pulmonary arteries and veins in anaesthetized cats. Br. J. Pharmacol., 1997, 121(4), 679-686.
158. McCormack, D.G.; Mak, J.C.; Coupe, M.O.; Barnes, P.J. Calcitonin gene-related peptide vasodilation of human pulmonary vessels. J. Appl. Physiol., 1989, 67(3), 1265-1270.
159. Gumusel, B.; Hao, Q.; Hyman, A.L.; Kadowitz, P.J.; Champion, H.C.; Chang, J.K.; Mehta, J.L.; Lippton, H. Analysis of responses to adrenomedullin-(13-52) in the pulmonary vascular bed of rats. Am. J. Physiol. Heart Circ. Physiol., 1998, 274(4), H1255-H1263.
160. Yang, B.C.; Lippton, H.; Gumusel, B.; Hyman, A.; Mehta, J.L. Adrenomedullin dilates rat pulmonary artery rings during hypoxia: role of nitric oxide and vasodilator prostaglandins. J. Cardiovasc. Pharmacol., 1996, 28(3), 458-462.
161. Wisskirchen, F.M.; Burt, R.P.; Marshall, I. Pharmacological characterization of CGRP receptors mediating relaxation of the rat pulmonary artery and inhibition of twitch responses of the rat vas deferens. Br. J. Pharmacol., 1998, 123(8), 1673-1683.
162. Fisher, R.A.; Robertson, S.M.; Olson, M.S. Stimulation and homologous desensitization of calcitonin gene-related peptide receptors in cultured beating rat heart cells. Endocrinology, 1988, 123(1), 106-112.
163. Wang, X.; Fiscus, R.R. Calcitonin gene-related peptide increases cAMP, tension, and rate in rat atria. Am. J. Physiol. Regul. Integr. Comp. Physiol., 1989, 256(2), R421-R428.
164. Jia, Y.; Yang, J.; Pan, C.; Geng, B.; Zhang, J.; Xiao, Y.; Zhao, J.; Gerns, H.; Yang, J.; Chang, J.K.; Wen, J.K.; Tang, C.S.; Qi, Y.F. Intermedin1-53 protects the heart against isoproterenol-induced ischemic injury in rats. Eur. J. Pharmacol., 2006, 549(1-3), 117-123.
165. Münzel, G.; Schlier, A.; Schreckenberg, R.; Abdallah, Y.; Schlüter, K. Rat intermedin1-47 does not improve functional recovery in postischemic hearts. Naunyn-Schmiedeberg's Arch. Pharmacol., 2011, 384(6), 535-542.
166. Szokodi, I.; Kinnunen, P.; Tavi, P.; Weckström, M.; Tóth, M.; Ruskoaho, H. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation, 1998, 97(11), 1062-1070.
167. Terata, K.; Miura, H.; Liu, Y.; Loberiza, F.; Gutterman, D.D. Human coronary arteriolar dilation to adrenomedullin: role of nitric oxide and K+ channels. Am. J. Physiol. Heart Circ. Physiol., 2000, 279(6), H2620-H2626.
168. Pires, A.L.; Pinho, M.; Sena, C.M.; Seica, R.; Leite-Moreira, A.F. Intermedin elicits a negative inotropic effect in rat papillary muscles mediated by endothelial-derived nitric oxide. Am. J. Physiol. Heart Circ. Physiol., 2012, 302(5), H1131-H1137.
169. Dong, F.; Taylor, M.M.; Samson, W.K.; Ren, J. Intermedin (adrenomedullin-2) enhances cardiac contractile function via a protein kinase C-and protein kinase A-dependent pathway in murine ventricular myocytes. J. Appl. Physiol., 2006, 101(3), 778-784.
170. Saetrum Opgaard, O.; Hasbak, P.; de Vries, R.; Saxena, P.R.; Edvinsson, L. Positive inotropy mediated via CGRP receptors in isolated human myocardial trabeculae. Eur. J. Pharmacol., 2000, 397(2-3), 373-382.
171. Katori, T.; Hoover, D.B.; Ardell, J.L.; Helm, R.H.; Belardi, D.F.; Tocchetti, C.G.; Forfia, P.R.; Kass, D.A.; Paolocci, N. Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure. Circ. Res., 2005, 96(2), 234-243.
172. Bell, D.; McDermott, B.J. Calcitonin gene-related peptide stimulates a positive contractile response in rat ventricular cardiomyocytes. J. Cardiovasc. Pharmacol., 1994, 23(6), 1011-1021.
173. Huang, M.; Knight, P.R.; Izzo, J.L. Ca2+-induced Ca2+ release involved in positive inotropic effect mediated by CGRP in ventricular myocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol., 1999, 276(1), R259-R264.
174. Schlier, A.; Schreckenberg, R.; Abdallah, Y.; Krasteva, G.; Piper, H.M.; Pfeil, U.; Kummer, W.; Schlüter, K.D. CGRP-α responsiveness of adult rat ventricular cardiomyocytes from normotensive and spontaneously hypertensive rats. Eur. J. Cell. Biol., 2009, 88(4):227-241.
175. Ihara, T.; Ikeda, U.; Tate, Y.; Ishibashi, S.; Shimada, K. Positive inotropic effects of adrenomedullin on rat papillary muscle. Eur. J. Pharmacol., 2000, 390(1-2), 167-172.
176. Ikenouchi, H.; Kangawa, K.; Matsuo, H.; Hirata, Y. Negative inotropic effect of adrenomedullin in isolated adult rabbit cardiac ventricular myocytes. Circulation, 1997, 95(9), 2318-2324.
177. Fujisawa, Y.; Nagai, Y.; Miyatake, A.; Takei, Y.; Miura, K.; Shoukouji, T.; Nishiyama, A.; Kimura, S.; Abe, Y. Renal effects of a new member of adrenomedullin family, adrenomedullin2, in rats. Eur. J. Pharmacol. 2004, 497(1), 75-80.
178. Haynes, J.M.; Cooper, M.E. Adrenomedullin and calcitonin generelated peptide in the rat isolated kidney and in the anaesthetised rat: in vitro and in vivo effects. Eur. J. Pharmacol., 1995, 280(1), 91-94.
179. Elhawary, A.M.; Poon, J.; Pang, C.C. Effects of calcitonin generelated peptide receptor antagonists on renal actions of adrenomedullin. Br. J. Pharmacol., 1995, 115(7), 1133-1140.
180. Hjelmqvist, H.; Keil, R.; Mathai, M.; Hubschle, T.; Gerstberger, R. Vasodilation and glomerular binding of adrenomedullin in rabbit kidney are not CGRP receptor mediated. Am. J. Physiol. Regul. Integr. Comp. Physiol., 1997, 273(2), R716-R724.
181. Majid, D.S.; Kadowitz, P.J.; Coy, D.H.; Navar, L.G. Renal responses to intra-arterial administration of adrenomedullin in dogs. Am. J. Physiol. Renal Physiol., 1996, 270(1), F200-F205.
182. Wangensteen, R.; Quesada, A.; Sainz, J.; Duarte, J.; Vargas, F.; Osuna, A. Role of endothelium-derived relaxing factors in adrenomedullin-induced vasodilation in the rat kidney. Eur. J. Pharmacol., 2002, 444(1-2), 97-102.
183. Edwards, R.M.; Trizna, W.; Stack, E.; Aiyar, N. Effect of adrenomedullin on cAMP levels along the rat nephron: comparison with CGRP. Am. J. Physiol. Renal Physiol., 1996; 271(4), F895-F899.
184. Reslerova, M.; Loutzenhiser, R. Renal microvascular actions of calcitonin gene-related peptide. Am. J. Physiol. Renal Physiol., 1998, 274(6), F1078-F1085.
185. Ay I, Tuncer M. Mechanism of CGRP-induced vasodilation in the rat isolated perfused kidney. Pharmacology, 2004, 71(4) 209-215.
186. Kurtz, A.; Schurek, H.J.; Jelkmann, W.; Muff, R.; Lipp, H.P.; Heckmann, U.; Eckardt, K.U.; Scholz, H.; Fischer, J.A.; Bauer, C. Renal mesangium is a target for calcitonin gene-related peptide. Kidney Int., 1989, 36(2), 222-227.
187. Edwards, R.M.; Trizna, W. Calcitonin gene-related peptide: effects on renal arteriolar tone and tubular cAMP levels. Am. J. Physiol. Renal Physiol., 1990, 258(1), F121-F125.
188. Nishimatsu, H.; Hirata, Y.; Shindo, T.; Kurihara, H.; Kakoki, M.; Nagata, D.; Hayakawa, H.; Satonaka, H.; Sata, M.; Tojo, A.; Suzuki, E.; Kangawa, K.; Matsuo, H.; Kitamura, T.; Nagai R. Role of endogenous adrenomedullin in the regulation of vascular tone and ischemic renal injury. Circ. Res., 2002; 90(6), 657-663.
189. Leclerc, M.; Brunette, M.G. The paradoxical effect of adrenomedullin on Na+ transport by the renal distal tubule luminal membrane. Mol. Cell Endocrinol., 2000, 164(1-2), 159-167.
190. Osajima, A.; Mutoh, Y.; Uezono, Y.; Kawamura, M.; Izumi, F.; Takasugi, M.; Kuroiwa, A. Adrenomedullin increases cyclic AMP more potently than CGRP and amylin in rat renal tubular basolateral membranes. Life Sci., 1995, 57(5), 457-462.
191. Hashitani, H.; Lang, R.J.; Mitsui, R.; Mabuchi, Y.; Suzuki, H. Distinct effects of CGRP on typical and atypical smooth muscle cells involved in generating spontaneous contractions in the mouse renal pelvis. Br. J. Pharmacol., 2009, 158(8), 2030-2045.
192. Taylor, M.M.; Samson, W.K. Stress hormone secretion is altered by central administration of intermedin/adrenomedullin-2. Brain Res., 2005, 1045(1-2), 199-205.
193. Samson, W.K.; Resch, Z.T.; Murphy, T.C.; Vargas, T.T.; Schell, D.A. Adrenomedullin: Is there physiological relevance in the pathology and pharmacology? Physiology, 1999, 14(6), 255-259.
194. Nagaya N. Satoh T. Nishikimi T. Uematsu M. Furuichi S. Sakamaki F. Oya H. Kyotani S. Nakanishi N. Goto Y. Masuda Y. Miyatake K. Kangawa K. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation, 2000, 101(5):498-503.
195. Touyz, R.M.; Schiffrin, E.L. Reactive oxygen species in vascular biology: implications in hypertension. Histochem. Cell Biol., 2004, 122(4), 339-352.
196. Li, J.; Shah, A.M. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2004, 287(5), R1014-R1030.
197. Cai, H.; Harrison, D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res., 2000, 87(10), 840-844.
198. Wardlaw, J.M.; Sandercock, P.A.; Dennis, M.S.; Starr, J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke, 2003, 34(3), 806-812.
199. Chen, L.; Kis, B.; Busija, D.W.; Yamashita, H.; Ueta, Y. Adrenomedullin protects rat cerebral endothelial cells from oxidant damage in vitro. Regul. Pept., 2005; 130(1-2), 27-34.
200. Xia, C.F.; Yin, H.; Borlongan, C.V.; Chao, J.; Chao, L. Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum. Gene. Ther., 2004, 15(12), 1243-1254.
201. Xia, C.; Yin, H.; Borlongan, C.V.; Chao, J.; Chao, L. Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp. Neurol., 2006, 197(2), 521-530.
202. Hagiwara, M.; Bledsoe, G.; Yang, Z.; Smith, R.S.; Chao, L.; Chao, J. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am. J. Physiol. Renal Physiol., 2008, 295(6), F1735-F1743.
203. Aslam, M.; Gündüz, D.; Schuler, D.; Li, L.; Sharifpanah, F.; Sedding, D.; Piper, H.M.; Noll, T. Intermedin induces loss of coronary microvascular endothelial barrier via derangement of actin cytoskeleton: role of RhoA and Rac1. Cardiovasc. Res., 2011, 92(2), 276-286.
204. Cai, Y.; Xu, M.J.; Teng, X.; Zhou, Y.B.; Chen, L.; Zhu, Y.; Wang, X.; Tang, C.S.; Qi, Y.F. Intermedin inhibits vascular calcification by increasing the level of matrix gamma-carboxyglutamic acid protein. Cardiovasc. Res., 2010, 85(4), 864-873.
205. Aslam, M.; Pfeil, U.; Gündüz, D.; Rafiq, A.; Kummer, W.; Piper, H.; Noll, T. Intermedin (adrenomedullin2) stabilizes the endothelial barrier and antagonizes thrombin-induced barrier failure in endothelial cell monolayers. Br. J. Pharmacol., 2012, 165(1), 208-222.
206. Smith, R.S.; Gao, L.; Bledsoe, G.; Chao, L.; Chao, J. Intermedin is a new angiogenic growth factor. Am. J. Physiol. Heart. Circ. Physiol., 2009, 297(3), H1040-H1047.
207. Albertin, G.; Sorato, E.; Oselladore, B.; Mascarin, A.; Tortorella, C.; Guidolin, D. Involvement of vascular endothelial growth factor signaling in CLR/RAMP1 and CLR/RAMP2-mediated proangiogenic effect of intermedin on human vascular endothelial cells. Int. J. Mol. Med., 2010, 26(2), 289-294.
208. Luecke, T.; Meinhardt, J.P.; Herrmann, P.; Weiss, A.; Quintel, M.; Pelosi, P. Oleic acid vs saline solution lung lavage-induced acute lung injury: effects on lung morphology, pressure-volume relationships, and response to positive end-expiratory pressure. Chest, 2006, 130(2), 392-401.
209. Yu, X.M.; Liu, X.M.; Qi, Y.F.; Zhang, Z.G.; Tang, C.S. The protective effects of intermedin1-53 on oleic acid induced acute lung injury in rats. Zhonghua Jie He He Hu Xi Za Zhi, 2006; 29(12), 808-811.
210. Yang, J.H.; Qi, Y.; Jia, Y.; Pan, C.; Zhao, J.; Yang, J.; Chang, J.K.; Tang, C.S. Protective effects of intermedin/adrenomedullin2 on ischemia/reperfusion injury in isolated rat hearts. Peptides, 2005, 26(3), 501-507.
211. Song, J.; Teng, X.; Cai, Y.; Tang, C.; Qi, Y. Activation of Akt/GSK-3β signaling pathway is involved in intermedin1-53 protection against myocardial apoptosis induced by ischemia/ reperfusion. Apoptosis, 2009, 14(11), 1299-1307.
212. Zhao, L.; Peng, D.Q.; Zhang, J.; Song, J.Q.; Teng, X.; Yu, Y.; Tang, C.S.; Qi, Y.F. Extracellular signal-regulated kinase 1/2 activation is involved in intermedin1-53 attenuating myocardial oxidative stress injury induced by ischemia/reperfusion. Peptides, 2012, 33(2), 329-335.
213. Teng, X.; Song, J.; Zhang, G.; Cai, Y.; Yuan, F.; Du, J.; Tang, C.; Qi, Y. Inhibition of endoplasmic reticulum stress by intermedin1-53 protects against myocardial injury through a PI3 kinase-Akt signaling pathway. J. Mol. Med. (Berl.), 2011, 89(12), 1195-1205.
214. Zhang, H.; Jiang, W.; Liu, J.; Li, Y.; Chen, C.; Xin, H.; Huang, D.J. Intermedin is upregulated and has protective roles in a mouse ischemia/reperfusion model. Hypertens. Res., 2009, 32(10), 861-868.
215. Yang, J.H.; Cai, Y.; Duan, X.H.; Ma, C.G.; Wang, X.; Tang, C.S.; Qi, Y.F. Intermedin1-53 inhibits rat cardiac fibroblast activation induced by angiotensin II. Regul. Pept., 2009, 158(1-3), 19-25.
216. Yang, J.H.; Ma, C.G.; Cai, Y.; Pan, C.S.; Zhao, J.; Tang, C.S.; Qi, Y.F. Effect of intermedin1-53 on angiotensin II-induced hypertrophy in neonatal rat ventricular myocytes. J. Cardiovasc. Pharmacol., 2010, 56(1), 45-52.
217. Du, X.; Cao, Y.; Xue, P.; Lin, Z.; Zeng, Z.; Xia, Q. Protective effect of intermedin on myocardial cell in a rat model of severe acute pancreatitis. Cell. Mol. Biol. Lett., 2011, 16(3), 462-476.
218. Hosomi, N.; Ohyama, H.; Takahashi, T.; Shinomiya, K.; Naya, T.; Ban, C.R.; Osaka, K.; Kohno, M.; Koziol, J.A. Plasma adrenomedullin and carotid atherosclerosis in atherothrombotic ischemic stroke. J. Hypertens., 2004, 22(10), 1945-1951.
219. Kuwasako, K.; Kida, O.; Kitamura, K.; Kato, J.; Eto, T. Plasma adrenomedullin in cerebrovascular disease: a possible indicator of endothelial injury. Int. Angiol., 1997, 16(4), 272-279.
220. Hirose, T.; Totsune, K.; Nakashige, Y.; Metoki, H.; Kikuya, M.; Ohkubo, T.; Hara, A.; Satoh, M.; Inoue, R.; Asayama, K.; Kondo, T.; Kamide, K.; Katsuya, T.; Ogihara, T.; Izumi, S.; Rakugi, H.; Takahashi, K.; Imai Y. Influence of adrenomedullin 2/intermedin gene polymorphism on blood pressure, renal function and silent cerebrovascular lesions in Japanese: the Ohasama study. Hypertens. Res., 2011, 34(12), 1327-1332.
221. Schaeffer, C.; Vandroux, D.; Thomassin, L.; Athias, P.; Rochette, L.; Connat, J. Calcitonin gene-related peptide partly protects cultured smooth muscle cells from apoptosis induced by an oxidative stress via activation of ERK1/2 MAPK. Biochim. Biophys. Acta, 2003, 1643(1-3), 65-73.
222. Townsend, P.A.; Cutress, R.I.; Carroll, C.J.; Lawrence, K.M.; Scarabelli, T.M.; Packham, G.; Stephanou, A.; Latchman, D.S. BAG-1 proteins protect cardiac myocytes from simulated ischemia/ reperfusion-induced apoptosis via an alternate mechanism of cell survival independent of the proteasome. J. Biol. Chem., 2004, 279(20), 20723-20728.
223. Bell, D.; Zhao, Y.; McCoy, F.P.; Devine, A.B.; McDermott, B.J. Differential effects of an anti-oxidant intervention on cardiomyocyte expression of adrenomedullin and intermedin and their receptor components in chronic nitric oxide deficiency. Cell Physiol. Biochem., 2007, 20(5), 269-282.
224. Bell, D.; Zhao, Y.; McCoy, F.P.; Devine, A.B.; McDermott, B.J. Expression of the counter-regulatory peptide intermedin is augmented in the presence of oxidative stress in hypertrophied cardiomyocytes. Cell. Physiol. Biochem., 2008, 21(5-6), 409-420.
225. Hirose, T.; Totsune, K.; Mori, N.; Morimoto, R.; Hashimoto, M.; Nakashige, Y.; Metoki, H.; Asayama, K.; Kikuya, M.; Ohkubo, T.; Hashimoto, J.; Sasano, H.; Kohzuki, M.; Takahashi, K.; Imai, Y. Increased expression of adrenomedullin 2/intermedin in rat hearts with congestive heart failure. Eur. J. Heart Fail., 2008, 10(9), 840-849.
226. Kim, W.; Moon, S.O.; Sung, M.J.; Kim, S.H.; Lee, S.; So, J.; Park, S.K. Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. FASEB J., 2003, 17(13), 1937-1939.
227. Nagaya, N.; Mori, H.; Murakami, S.; Kangawa, K.; Kitamura, S. Adrenomedullin: angiogenesis and gene therapy. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 288(6), R1432-R1437.
228. Mishima, T.; Ito, Y.; Hosono, K.; Tamura, Y.; Uchida, Y.; Hirata, M.; Suzsuki, T.; Amano, H.; Kato, S.; Kurihara, Y.; Kurihara, H.; Hayashi, I.; Watanabe, M.; Majima, M. Calcitonin gene-related peptide facilitates revascularization during hindlimb ischemia in mice. Am. J. Physiol. Heart Circ. Physiol., 2011, 300(2), H431-H439.
229. Zheng, S.; Li, W.; Xu, M.; Bai, X.; Zhou, Z.; Han, J.; Shyy, J.Y.; Wang, X. Calcitonin gene-related peptide promotes angiogenesis via AMP-activated protein kinase. Am. J. Physiol. Cell Physiol., 2010, 299(6), C1485-1492.
230. Kim, S.; Kim, J.; Lee, S.; Park, J. Adrenomedullin protects against hypoxia/reoxygenation-induced cell death by suppression of reactive oxygen species via thiol redox systems. FEBS Lett., 2010, 584(1), 213-218.
231. Sørhaug, S.; Steinshamn, S.; Munkvold, B.; Waldum, H.L. Release of neuroendocrine products in the pulmonary circulation during intermittent hypoxia in isolated rat lung. Respir. Physiol. Neurobiol., 2008, 162(1), 1-7.
232. Tjen-A-Looi, S.; Kraiczi, H.; Ekman, R.; Keith, I.M. Sensory CGRP depletion by capsaicin exacerbates hypoxia-induced pulmonary hypertension in rats. Regul. Pept., 1998, 74(1), 1-10.
233. Janssen, P.L.; Tucker, A. Calcitonin gene-related peptide modulates pulmonary vascular reactivity in isolated rat lungs. J. Appl. Physiol., 1994, 77(1), 142-146.
234. Qing X, Keith IM. Targeted blocking of gene expression for CGRP receptors elevates pulmonary artery pressure in hypoxic rats. Am. J. Physiol. Lung Cell Mol. Physiol., 2003, 285 (1): L86-96.
235. Mannan, M.M.; Springall, D.R.; Enard, C.; Moradoghli-Haftvani, A.; Eddahibi, S.; Adnot, S.; Polak, J.M. Decreased endotheliumdependent pulmonary vasodilator effect of calcitonin gene-related peptide in hypoxic rats contrasts with increased binding sites. Eur. Respir. J., 1995, 8(12), 2029-2037.
236. Gout, B.; Quiniou, M.J.; Khandoudi, N.; Le Dantec, C.; Saiag, B. Impaired endothelium-dependent relaxation by adrenomedullin in monocrotaline-treated rat arteries. Eur. J. Pharmacol., 1999, 380(1), 23-30.
237. Matsui, H.; Shimosawa, T.; Itakura, K.; Guanqun, X.; Ando, K.; Fujita, T. Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation, 2004, 109(18), 2246-2251.
238. Wang, M.; Ji, P.; Wang, R.; Zhao, L.; Xia, Z. TRPV1 agonist capsaicin attenuates lung ischemia-reperfusion injury in rabbits. J. Surg. Res., 2012, 173(1), 153-160.
239. Chattergoon, N.N.; D'Souza, F.M.; Deng, W.; Chen, H.; Hyman, A.L.; Kadowitz, P.J.; Jeter, J.R. Jr. Antiproliferative effects of calcitonin gene-related peptide in aortic and pulmonary artery smooth muscle cells. Am. J. Physiol. Lung. Cell. Mol. Physiol., 2005, 288(1), L202-211.
240. Li, X.; Hu, C.; Wu, W.; Zhang, W.; Zou, X.; Li, Y. Inhibitory effect of calcitonin gene-related peptide on hypoxia-induced rat pulmonary artery smooth muscle cells proliferation: Role of ERK1/2 and p27. Eur. J. Pharmacol., 2012, 679(1-3), 117-126.
241. Vadivel, A.; Abozaid, S.; van Haaften, T.; Sawicka, M.; Eaton, F.; Chen, M.; Thébaud, B. Adrenomedullin promotes lung angiogenesis, alveolar development, and repair. Am. J. Respir. Cell. Mol. Biol., 2010, 43(2), 152-160.
242. Champion, H.C.; Bivalacqua, T.J.; Toyoda, K.; Heistad, D.D.; Hyman, A.L.; Kadowitz, P.J. In vivo gene transfer of preprocalcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation, 2000, 101(8), 923-930.
243. Bivalacqua, T.J.; Hyman, A.L.; Kadowitz, P.J.; Paolocci, N.; Kass, D.A.; Champion, H.C. Role of calcitonin gene-related peptide (CGRP) in chronic hypoxia-induced pulmonary hypertension in the mouse. Influence of gene transfer in vivo. Regul. Pept., 2002, 108(2-3), 129-133.
244. Zhao, Q.; Liu, Z.; Wang, Z.; Yang, C.; Liu, J.; Lu, J. Effect of prepro-calcitonin gene-related peptide-expressing endothelial progenitor cells on pulmonary hypertension. Ann. Thorac. Surg., 2007, 84(2), 544-552.
245. Murakami, S.; Kimura, H.; Kangawa, K.; Nagaya, N. Physiological significance and therapeutic potential of adrenomedullin in pulmonary hypertension. Cardiovasc. Hematol. Disord. Drug Targets, 2006, 6(2), 125-132.
246. Qi, J.G.; Ding, Y.G.; Tang, C.S.; Du, J.B. Chronic administration of adrenomedullin attenuates hypoxic pulmonary vascular structural remodeling and inhibits proadrenomedullin N-terminal 20-peptide production in rats. Peptides, 2007, 28(4), 910-919.
247. Yoshihara, F.; Nishikimi, T.; Horio, T.; Yutani, C.; Takishita, S.; Matsuo, H.; Ohe, T.; Kangawa, K. Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline. Eur. J. Pharmacol., 1998, 355(1), 33-39.
248. Nagaya, N.; Okumura, H.; Uematsu, M.; Shimizu, W.; Ono, F.; Shirai, M.; Mori, H.; Miyatake, K.; Kangawa, K. Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am. J. Physiol. Heart Circ. Physiol., 2003, 285(5), H2125-2131.
249. von der Hardt, K.; Kandler, M.A.; Chada, M.; Cubra, A.; Schoof, E.; Amann, K.; Rascher, W.; Dötsch, J. Brief adrenomedullin inhalation leads to sustained reduction of pulmonary artery pressure. Eur. Respir. J., 2004, 24(4), 615-623.
250. Bauer, N.R.; Moore, T.M.; McMurtry, I.F. Rodent models of PAH: are we there yet? Am. J. Physiol. Lung Cell. Mol. Physiol., 2007, 293(3), L580-582.
251. Bartosik, I.; Eskilsson, J.; Ekman, R.; Akesson, A.; Scheja, A. Correlation between plasma concentrations of calcitonin gene related peptide and pulmonary pressure in patients with systemic sclerosis. Ann. Rheum. Dis., 2002, 61(3), 261-263.
252. Yoshibayashi, M.; Kamiya, T.; Kitamura, K.; Saito, Y.; Kangawa, K.; Nishikimi, T.; Matsuoka, H.; Eto, T.; Matsuo, H. Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients <20 years of age. Am. J. Cardiol., 1997, 79(11), 1556-1558.
253. Kakishita, M.; Nishikimi, T.; Okano, Y.; Satoh, T.; Kyotani, S.; Nagaya, N.; Fukushima, K.; Nakanishi, N.; Takishita, S.; Miyata, A.; Kangawa, K.; Matsuo, H.; Kunieda, T. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin. Sci. (Lond.), 1999, 96(1), 33-39.
254. Vizza, C.D.; Letizia, C.; Badagliacca, R.; Sciomer, S.; Poscia, R.; Della Rocca, G.; Iacoboni, C.; Leonardo de, L.; Quattrucci, S.; Dario, C.; Luigi, P.; Fedele, F. Plasma adrenomedullin and endothelin-1 concentration during low-dose dobutamine infusion: Relationship between pulmonary uptake and pulmonary vascular pressure/ flow characteristics. Regul. Pept., 2006, 136(1-3), 85-91.
255. Nagaya, N.; Kyotani, S.; Uematsu, M.; Ueno, K.; Oya, H.; Nakanishi, N.; Shirai, M.; Mori, H.; Miyatake, K.; Kangawa, K. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation, 2004, 109(3), 351-356.
256. Müller-Redetzky, H.C.; Kummer, W.; Pfeil, U.; Hellwig, K.; Will, D.; Paddenberg, R.; Tabeling, C.; Hippenstiel, S.; Suttorp, N.; Witzenrath, M. Intermedin stabilized endothelial barrier function and attenuated ventilator-induced lung injury in mice. PLoS One, 2012, 7(5), e35832. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341380/
257. Kato, K.; Yin, H.; Agata, J.; Yoshida, H.; Chao, L.; Chao, J. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am. J. Physiol. Heart Circ. Physiol., 2003, 285(4), H1506-H1514.
258. Beltowski, J.; Jamroz, A. Adrenomedullin-what do we know 10 years since its discovery? Pol. J. Pharmacol., 2004, 56(1), 5-27.
259. Grossini, E.; Molinari, C.; Mary, D.A.; Uberti, F.; Caimmi, P.P.; Vacca, G. Intracoronary intermedin1-47 augments cardiac perfusion and function in anesthetized pigs: role of calcitonin receptors and β-adrenoreceptor-mediated nitric oxide release. J. Appl. Physiol., 2009, 107(4), 1037-1050.
260. Ren, Y.S.; Ma, T.G.; Wang, H.B.; Yu, S.Q. Protective effects of CGRP on myocardial cell injury and calcium and magnesium contents following severe hypoxia and simulated reperfusion. Med. Sci. Res., 1993, 21, 177-178.
261. Zhao, F.; Guo, Z.; Wang, P. Calcitonin gene related peptide (CGRP) inhibits norepinephrine induced apoptosis in cultured rat cardiomyocytes not via PKA or PKC pathways. Neurosci. Lett., 2010, 482(2), 163-166.
262. Sueur, S.; Pesant, M.; Rochette, L.; Connat, J. Antiapoptotic effect of calcitonin gene-related peptide on oxidative stress-induced injury in H9c2 cardiomyocytes via the RAMP1/CRLR complex. J. Mol. Cell Cardiol., 2005, 39(6), 955-963.
263. Tokudome, T.; Horio, T.; Yoshihara, F.; Suga, S.; Kawano, Y.; Kohno, M.; Kangawa, K. Adrenomedullin inhibits doxorubicininduced cultured rat cardiac myocyte apoptosis via a cAMPdependent mechanism. Endocrinology, 2002, 143(9), 3515-3521.
264. Franco-Cereceda, A.; Saria, A.; Lundberg, J.M. Ischemia and changes in contractility induce release of CGRP but not NPY from the isolated perfused guinea-pig heart. Acta Physiol. Scand., 1987, 131(2), 319-320.
265. Zhang, J.F.; Liu, J.; Liu, X.Z.; Li, M.Y.; Sheng, S.L.; Zhang, W.J. The effect of calcitonin gene-related peptide on ischemic reperfusion-induced arrhythmias in rats. Int. J. Cardiol., 1994, 46(1), 33-36.
266. Yoshitomi, Y.; Nishikimi, T.; Kojima, S.; Kuramochi, M.; Takishita, S.; Matsuoka, H.; Miyata, A.; Matsuo, H.; Kangawa, K. Plasma levels of adrenomedullin in patients with acute myocardial infarction. Clin. Sci. (Lond.), 1998, 94(2), 135-139.
267. Asakawa, H.; Nishikimi, T.; Suzuki, T.; Hara, S.; Tsubokou, Y.; Yagi, H.; Yabe, A.; Tsuchiya, N.; Horinaka, S.; Kangawa, K.; Matsuoka, H. Elevation of two molecular forms of adrenomedullin in plasma and urine in patients with acute myocardial infarction treated with early coronary angioplasty. Clin. Sci. (Lond.), 2001, 100(1), 117-126.
268. Richards, A.M.; Nicholls, M.G.; Yandle, T.G.; Frampton, C.; Espiner, E.A.; Turner, J.G.; Buttimore, R.C.; Lainchbury, J.G.; Elliott, J.M.; Ikram, H.; Crozier, I.G.; Smyth, D.W. Plasma Nterminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation, 1998, 97(19), 1921-1929.
269. Khan, S.Q.; O'Brien, R.J.; Struck, J.; Quinn, P.; Morgenthaler, N.; Squire, I.; Davies, J.; Bergmann, A.; Ng, L.L. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction. J. Am. Coll. Cardiol., 2007, 49(14), 1525-1532.
270. Lechleitner, P.; Genser, N.; Mair, J.; Dienstl, A.; Haring, C.; Wiedermann, C.J.; Puschendorf, B.; Saria, A.; Dienstl, F. Calcitonin gene-related peptide in patients with and without early reperfusion after acute myocardial infarction. Am. Heart J., 1992, 124(6), 1433-1439.
271. Wahrborg, P.; Eliasson, T.; Edvardsson, N.; Ekman, R.; Mannheimer, C.; Hedner, T. Acute ischemic chest pain is not associated with increased calcitonin gene-related peptide (CGRP) levels in peripheral plasma nor in the coronary circulation. Scand. Cardiovasc. J., 1999, 33(5), 295-299.
272. Källner, G. Release and effects of calcitonin gene-related peptide in myocardial ischaemia. Scand. Cardiovasc. J. Suppl., 1998, 49, 1-35.
273. Myocardial infarction redefined-A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur. Heart J., 2000, 21(18), 1502-1513.
274. Bell, D.; Zhao, Y.; Kelso, E.J.; McHenry, E.M.; Rush, L.M.; Lamont, V.M.; Nicholls, D.P.; McDermott, B.J. Upregulation of adrenomedullin and its receptor components during cardiomyocyte hypertrophy induced by chronic inhibition of nitric oxide synthesis in rats. Am. J. Physiol. Heart Circ. Physiol., 2006, 290(2), H904-H914.
275. Zatz, R.; Baylis, C. Chronic nitric oxide inhibition model six years on. Hypertension, 1998, 32(6), 958-964.
276. Bell, D.; Campbell, M.; Wang, X.; Earle, J.A.; Cosby, S.L.; McDermott, B.J. Adrenomedullin gene delivery is cardioprotective in a model of chronic nitric oxide deficiency combining pressure overload, oxidative stress and cardiomyocyte hypertrophy. Cell Physiol. Biochem., 2010, 26(3), 383-394.
277. Peng, J.; Xiao, J.; Ye, F.; Deng, H.; Li, Y. Inhibition of cardiac tumor necrosis factor-α production by calcitonin gene-related peptide-mediated ischemic preconditioning in isolated rat hearts. Eur. J. Pharmacol., 2000, 407(3), 303-308.
278. Li, D.; Li, N.; Chen, Q.; Guo, R.; Xu, P.; Deng, H.; Li, Y.J. Calcitonin gene-related peptide-mediated cardioprotection of postconditioning in isolated rat hearts. Regul. Pept., 2008, 147(1-3), 4-8.
279. Chao, J.; Kato, K.; Zhang, J.J.; Dobrzynski, E.; Wang, C.; Agata, J.; Chao, L. Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. Peptides, 2001, 22(11), 1731-1737.
280. Dobrzynski, E.; Wang, C.; Chao, J.; Chao, L. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension, 2000, 36(6), 995-1001.
281. Niu, P.; Shindo, T.; Iwata, H.; Iimuro, S.; Takeda, N.; Zhang, Y.; Ebihara, A.; Suematsu, Y.; Kangawa, K.; Hirata, Y.; Nagai, R. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation, 2004, 109(14), 1789-1794.
282. Rahman, M.; Nishiyama, A.; Guo, P.; Nagai, Y.; Zhang, G.; Fujisawa, Y.; Fan, Y.Y.; Kimura, S.; Hosomi, N.; Omori, K.; Abe, Y.; Kohno, M. Effects of adrenomedullin on cardiac oxidative stress and collagen accumulation in aldosterone-dependent malignant hypertensive rats. J. Pharmacol. Exp. Ther., 2006, 318(3), 1323-1329.
283. Nakamura, R.; Kato, J.; Kitamura, K.; Onitsuka, H.; Imamura, T.; Marutsuka, K.; Asada, Y.; Kangawa, K.; Eto, T. Beneficial effects of adrenomedullin on left ventricular remodeling after myocardial infarction in rats. Cardiovasc. Res., 2002, 56(3), 373-380.
284. Nakamura, R.; Kato, J.; Kitamura, K.; Onitsuka, H.; Imamura, T.; Cao, Y.; Marutsuka, K.; Asada, Y.; Kangawa, K.; Eto, T. Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. Circulation, 2004, 110(4), 426-431.
285. Nishikimi, T.; Yoshihara, F.; Horinaka, S.; Kobayashi, N.; Mori, Y.; Tadokoro, K.; Akimoto, K.; Minamino, N.; Kangawa, K.; Matsuoka, H. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. Hypertension, 2003, 42(5), 1034-1041.
286. Rademaker, M.T.; Charles, C.J.; Espiner, E.A.; Nicholls, M.G.; Richards, A.M. Long-term adrenomedullin administration in experimental heart failure. Hypertension, 2002, 40(5), 667-672.
287. Willenbrock, R.; Langenickel, T.; Knecht, M.; Pagel, I.; Hohnel, K.; Philipp, S.; Dietz, R. Regulation of cardiac adrenomedullinmRNA in different stages of experimental heart failure. Life Sci., 1999, 65(21), 2241-2249.
288. Cueille, C.; Pidoux, E.; de Vernejoul, M.; Ventura-Clapier, R.; Garel, J. Increased myocardial expression of RAMP1 and RAMP3 in rats with chronic heart failure. Biochem. Biophys. Res. Commun., 2002, 294(2), 340-346.
289. Øie, E.; Vinge, L.E.; Andersen, G. Ø.; Yndestad, A.; Krobert, K.A.; Sandberg, C.; Ahmed, M.S.; Haug, T.; Levy, F.O.; Skomedal, T.; Attramadal, H. RAMP2 and RAMP3 mRNA levels are increased in failing rat cardiomyocytes and associated with increased responsiveness to adrenomedullin. J. Mol. Cell Cardiol., 2005, 38(1), 145-151.
290. Shen, Y.T.; Mallee, J.J.; Handt, L.K.; Gilberto, D.B.; Lynch, J.J. Jr.; Hargreaves, R.J.; Koblan, K.S.; Gould, R.J.; Kane, S.A. Effects of inhibition of alpha-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic heart failure. J. Cardiovasc. Pharmacol., 2003, 42(5), 656-661.
291. Helin, K.; Tikkanen, I.; Kiilavuori, K.; Naveri, H.; Fyhrquist, F. Calcitonin gene-related peptide is not elevated in rat plasma by heart failure or by neutral endopeptidase inhibition. Life Sci., 1994, 55(6), 471-477.
292. Hirayama, N.; Kitamura, K.; Imamura, T.; Kato, J.; Koiwaya, Y.; Tsuji, T.; Kangawa, K.; Eto, T. Molecular forms of circulating adrenomedullin in patients with congestive heart failure. J. Endocrinol., 1999, 160(2), 297-303.
293. Pousset, F.; Masson, F.; Chavirovskaia, O. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur. Heart. J., 2000, 21(12), 1009-1014.
294. Richards, A.M.; Doughty, R.; Nicholls, M.G.; MacMahon, S.; Sharpe, N.; Murphy, J.; Espiner, E.A.; Frampton, C.; Yandle, T.G.; Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J. Am. Coll. Cardiol., 2001, 37(7), 1781-1787.
295. Etoh, T.; Kato, J.; Takenaga, M.; Imamura, T.; Kitamura, K.; Koiwaya, Y.; Eto, T. Differential hormonal profiles of adrenomedullin and proadrenomedullin N-terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels. Clin. Cardiol., 1999, 22(2), 113-117.
296. Morgenthaler, N.G.; Struck, J.; Alonso, C.; Bergmann, A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin. Chem., 2005, 51(10), 1823-1829.
297. Maisel, A.; Mueller, C.; Nowak, R.M.; Peacock, W.F.; Ponikowski, P.; Mockel, M.; Hogan, C.; Wu, A.H.; Richards, M.; Clopton, P.; Filippatos, G.S.; Di Somma, S.; Anand, I.; Ng, L.L.; Daniels, L.B.; Neath, S.X.; Christenson, R.; Potocki, M.; McCord, J.; Hartmann, O.; Morgenthaler, N.G.; Anker, S.D. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) Trial. J. Am. Coll. Cardiol., 2011, 58(10), 1057-1067.
298. Elmas, E.; Lang, S.; Dempfle, C.E.; Kalsch, T.; Papassotiriou, J.; Morgenthaler, N.G.; Borggrefe, M.; Brueckmann, M. Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction. Int. J. Cardiol., 2008, 128(1), 107-111.
299. Taquet, H.; Komajda, M.; Grenier, O.; Belas, F.; Landault, C.; Carayon, A.; Lechat, P.; Grosgogeat, Y.; Legrand, J.C. Plasma calcitonin gene-related peptide decreases in chronic congestive heart failure. Eur. Heart J., 1992, 13(11), 1473-1476.
300. Hsu, J.H.; Yeh, J.L.; Dai, Z.K.; Chen, I.J.; Wu, J.R. Increased circulating calcitonin gene-related peptide in congestive heart failure caused by congenital heart disease. Int. Heart J., 2005 46(5), 867-875.
301. Nishikimi, T.; Karasawa, T.; Inaba, C.; Ishimura, K.; Tadokoro, K.; Koshikawa, S. Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: a pilot study. Circ. J., 2009, 73(5), 892-898.
302. Nakamura, M.;Yoshida, H.; Makita, S.; Arakawa, N.; Niinuma, H.; Hiramori, K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Circulation, 1997, 95(5), 1214-1221.
303. Shekhar, Y.C.; Anand, I.S.; Sarma, R.; Ferrari, R.; Wahi, P.L.; Poole-Wilson, P.A. Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. Am. J. Cardiol., 1991, 67(8), 732-736.
304. Anand, I.S.; Gurden J.; Wander, G.S.; O'Gara, P.; Harding, S.E.; Ferrari, R.; Cornacchiari, A.; Panzali, A.; Wahi, P.L.; Poole-Wilson, P.A. Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure. J. Am. Coll. Cardiol., 1991 17(1), 208-217.
305. Stevenson, R.N.; Roberts, R.H.; Timmis, A.D. Calcitonin generelated peptide: a haemodynamic study of a novel vasodilator in patients with severe chronic heart failure. Int. J. Cardiol., 1992, 37(3), 407-414.
306. Bergman, A.S.; Falt, K.; Odar-Cederlof, I.; Westman, L.; Takolander, R. Calcitonin gene-related peptide attenuates experimental ischemic renal failure in a rat model of reversible renal ischemic insult. Ren. Fail., 1994, 16(3), 351-357.
307. Mizutani, A.; Okajima, K.; Murakami, K.; Mizutani, S.; Kudo, K.; Uchino, T.; Kadoi, Y.; Noguchi, T. Activation of sensory neurons reduces ischemia/reperfusion-induced acute renal injury in rats. Anesthesiology, 2009, 110(2), 361-369.
308. Nagata, D.; Hirata, Y.; Suzuki, E.; Kakoki, M.; Hayakawa, H.; Goto, A.; Ishimitsu, T.; Minamino, N.; Ono, Y.; Kangawa, K.; Matsuo, H.; Omata, M. Hypoxia-induced adrenomedullin production in the kidney. Kidney Int., 1999, 55(4), 1259-1267.
309. Li, J.Z.; Wang, H.Y.; Tang, J.; Zou, W.Z. The effect of calcitoningene-related peptide on acute ischemia-reperfusion renal injury: ultrastructural and membrane lipid peroxidation studies. Ren. Fail., 1992 14(1),11-16.
310. Shah, K.G.; Rajan, D.; Jacob, A.; Wu, R.; Krishnasastry, K.; Nicastro, J.; Molmenti, E.P.; Coppa, G.F.; Wang, P. Attenuation of renal ischemia and reperfusion injury by human adrenomedullin and its binding protein. J. Surg. Res., 2010, 163(1), 110-117.
311. Oyar, E.O.; Kiris, I.; Gulmen, S.; Ceyhan, B.M.; Cure, M.C.; Delibas, N.; Lortlar, N.; Okutan, H. The protective effect of adrenomedullin on renal injury, in a model of abdominal aorta crossclamping. Thorac. Cardiovasc. Surg., 2012, 60(1), 5-10.
312. Niu, P.; Shindo, T.; Iwata, H.; Ebihara, A.; Suematsu, Y.; Zhang, Y.; Takeda, N.; Iimuro, S.; Hirata, Y.; Nagai, R. Accelerated cardiac hypertrophy and renal damage induced by angiotensin II in adrenomedullin knockout mice. Hypertens. Res., 2003, 26(9), 731-736.
313. Wang, C.; Dobrzynski, E.; Chao, J.; Chao, L. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am. J. Physiol. Renal Physiol., 2001, 280(6), F964-971.
314. Yoshihara, F.; Suga, S.; Yasui, N.; Horio, T.; Tokudome, T.; Nishikimi, T.; Kawano, Y.; Kangawa, K. Chronic administration of adrenomedullin attenuates the hypertension and increases renal nitric oxide synthase in Dahl salt-sensitive rats. Regul. Pept., 2005, 128(1), 7-13.
315. Nishikimi, T.; Wang, X.; Akimoto, K.; Tadokoro, K.; Mori, Y.; Ishikawa, Y.; Ishimura, K.; Yoshihara, F.; Minamino, N.; Kangawa, K.; Matsuoka, H. Alteration of renal adrenomedullin and its receptor system in the severely hypertensive rat: effect of diuretic. Regul. Pept., 2005, 124(1-3), 89-98.
316. Nishikimi, T; Yoshihara, F.; Kanazawa, A.; Okano, I.; Horio, T.; Nagaya, N.; Yutani, C.; Matsuo, H.; Matsuoka, H.; Kangawa, K. Role of increased circulating and renal adrenomedullin in rats with malignant hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 281(6), R2079-2087.
317. Dobrzynski, E.; Montanari, D.; Agata, J.; Zhu, J.; Chao, J.; Chao, L. Adrenomedullin improves cardiac function and prevents renal damage in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab., 2002, 283(6), E1291-1298.
318. Hiragushi, K.; Wada, J.; Eguchi, J.; Matsuoka, T.; Yasuhara, A.; Hashimoto, I.; Yamashita, T.; Hida, K.; Nakamura, Y.; Shikata, K.; Minamino, N.; Kangawa, K.; Makino, H. The role of adrenomedullin and receptors in glomerular hyperfiltration in streptozotocininduced diabetic rats. Kidney Int., 2004, 65(2), 540-550.
319. Ito, K.; Yoshii, H.; Asano, T.; Seta, K.; Mizuguchi, Y.; Yamanaka, M.; Tokonabe, S.; Hayakawa, M.; Asano, T. Adrenomedullin increases renal nitric oxide production and ameliorates renal injury in mice with unilateral ureteral obstruction. J. Urol., 2010, 183(4), 1630-1635.
320. Mukoyama, M.; Sugawara, A.; Nagae, T.; Mori, K.; Murabe, H.; Itoh, H.; Tanaka, I.; Nakao, K. Role of adrenomedullin and its receptor system in renal pathophysiology. Peptides, 2001, 22(11), 1925-1931.
321. Nagae, T.; Mori. K.; Mukoyama, M.; Kasahara, M.; Yokoi, H.; Suganami, T.; Sawai, K.; Yoshioka, T.; Koshikawa, M.; Saito, Y.; Ogawa, Y.; Kuwabara, T.; Tanaka, I.; Sugawara, A.; Kuwahara, T.; Nakao, K. Adrenomedullin inhibits connective tissue growth factor expression, extracellular signal-regulated kinase activation and renal fibrosis. Kidney Int., 2008, 74(1), 70-80.
322. Parameswaran, N.; Hall, C.C.; Bomberger, J.M.; Spielman, W.S. Regulation of adrenomedullin signaling in kidney interstitial fibroblasts. Cell. Physiol. Biochem., 2003, 13(6), 391-400.
323. Huang, H.; Ma, C.; Yang, M.; Tang, C.; Wang, H. Adrenomedullin impairs the profibrotic effects of transforming growth factor-beta1 through recruiting Smad6 protein in human renal tubular cells. Cell. Physiol. Biochem., 2005, 15(1-4), 117-124.
324. Totsune, K.; Takahashi, K.; Mackenzie, H.S.; Arihara, Z.; Satoh, F.; Sone, M.; Murakami, O.; Ito, S.; Brenner, B.M.; Mouri, T. Adrenomedullin and its receptor complexes in remnant kidneys of rats with renal mass ablation: decreased expression of calcitonin receptor-like receptor and receptor-activity modifying protein-3. Peptides, 2001, 22(11), 1933-1937
325. Ishihara, T.; Yokota, N.; Hisanaga, S.; Fujimoto, S.; Hirayama, N.; Kato, J.; Kitamura, K.; Eto, T. Increased plasma levels of mature form of adrenomedullin in patients with chronic renal failure. Clin. Nephrol., 1999, 52(2), 119-123.
326. Ishimitsu, T.; Tsukada, K.; Minami, J.; Ono, H.; Ohrui, M.; Hino, J.; Kangawa, K.; Matsuoka, H. Microsatellite DNA polymorphism of human adrenomedullin gene in type 2 diabetic patients with renal failure. Kidney Int., 2003, 63(6), 2230-2235.
327. McGregor, D.O.; Troughton, R.W.; Frampton, C.; Lynn, K.L.; Yandle, T.; Richards, A.M.; Nicholls, M.G. Hypotensive and natriuretic actions of adrenomedullin in subjects with chronic renal impairment. Hypertension, 2001, 37(5), 1279-1284.
328. Palla, R.; Parrini, M.; Panichi, V.; Andreini, B.; De Pietro, S.; Migliori, M.; Bianchi, A.M.; Giovannini, L.; Bertelli, A.; Bertelli, A.A. Acute effects of calcitonin gene related peptide on renal haemodynamics and renin and angiotensin II secretion in patients with renal disease. Int. J. Tissue React., 1995, 17(1), 43-49.